Targeting the androgen receptor: Improving outcomes for castration-resistant prostate cancer

Endocrine-Related Cancer

Volumn 11, Issue 3, 2004, Pages 459-476

  Scher, Howard I ^a,c   Buchanan, Grant ^b   Gerald, William ^c   Butler, Lisa M ^b   Tilley, Wayne D ^b,d  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b UNIVERSITY OF ADELAIDE   (Australia)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d HANSON INSTITUTE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

17 ALLYLAMINO 17 DEMETHOXYGELDANAMYCIN; ANDROGEN RECEPTOR; ANDROSTANOLONE; ANDROSTENEDIOL; ANTIANDROGEN; BICALUTAMIDE; DIETHYLSTILBESTROL; ESTRADIOL; ESTROGEN; FLUTAMIDE; GELDANAMYCIN; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; HYDROXYFLUTAMIDE; LEUPRORELIN; MEGESTROL ACETATE; NILUTAMIDE; PROSTATE SPECIFIC ANTIGEN; PROTEIN ARA54; PROTEIN ARA55; PROTEIN ARA70; REGULATOR PROTEIN; TESTOSTERONE; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; ANDROGEN THERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; CANCER CLASSIFICATION; CANCER RESISTANCE; CANCER SURVIVAL; CASTRATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DISEASE COURSE; DOSE TIME EFFECT RELATION; GENOTYPE; GROWTH INHIBITION; HORMONE ACTION; HORMONE RECEPTOR INTERACTION; HUMAN; LIGAND BINDING; MALE; MOUSE; NONHUMAN; OUTCOMES RESEARCH; PHENOTYPE; PROSTATE CANCER; REVIEW; SIGNAL TRANSDUCTION; TUMOR GROWTH;

ANIMALS; CASTRATION; DISEASE PROGRESSION; HUMANS; MALE; NEOPLASMS, HORMONE-DEPENDENT; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN;

EID: 4944246790     PISSN: 13510088     EISSN: None     Source Type: Journal    
DOI: 10.1677/erc.1.00525     Document Type: Review

References (118)

1. Agus DB, Cordon-Cardo C, Fox W, Drobnjak M, Koff A, Golde DW & Scher HI 1999 Prostate cancer cell cycle regulators: response to androgen withdrawal and development of androgen independence. Journal of the National Cancer Institute 91 1869-1876.
2. Akakura K, Akimoto S, Furuya Y & Ito H 1998 Incidence and characteristics of antiandrogen withdrawal syndrome in prostate cancer after treatment with chlormadinone acetate. European Urology 33 567-571.
3. Amler LC, Agus DB, LeDuc C, Sapinoso ML, Fox WD, Kern S, Lee D, Wang V, Leysens M, Higgins B, Martin J, Gerald W, Dracopoli N, Cordon-Cardo C, Scher HI & Hampton GM 2000 Dysregulated expression of androgen-responsive and nonresponsive genes in the androgen-independent prostate cancer xenograft model CWR22-R1. Cancer Research 60 6134-6141.
4. Anzick SL, Kononen J, Walker RL, Azorsa DO, Tanner MM, Guan XY, Sauter G, Kallioniemi OP, Trent JM & Meltzer PS 1997 AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer. Science 277 965-968.
5. Balk SP, Ko YJ & Bubley GJ 2003 Biology of prostate-specific antigen. Journal of Clinical Oncology 21 383-391.
6. Bentel JM & Tilley WD 1996 Androgen receptors in prostate cancer. Journal of Endocrinology 151 1-11.
7. Berrevoets CA, Umar A, Trapman J & Brinkmann AO 2004 Differential modulation of androgen receptor transcriptional activity by the nuclear receptor corepressor (N-CoR). Biochemical Journal 379 1147-1154.
8. Bissada NK & Kaczmarek AT 1995 Complete remission of hormone refractory adenocarcinoma of the prostate in response to withdrawal of diethylstilbestrol. Journal of Urology 153 1944-1945.
9. Bramlett KS, Dits NF, Sui X, Jorge MC, Zhu X & Jenster G 2001 Repression of androgen-regulated gene expression by dominant negative androgen receptors. Molecular and Cellular Endocrinology 183 19-28.
10. Bubendorf L, Kononen J, Koivisto P, Schraml P, Moch H, Gasser TC, Willi N, Mihatsch MJ, Sauter G & Kallioniemi OP 1999 Survey of gene amplifications during prostate cancer progression by high-throughout fluorescence in situ hybridization on tissue microarrays. Cancer Research 59 803-806.
11. Buchanan G, Yang M, Nahm SJ, Han G, Moore N, Bentel JM, Matusik RJ, Horsfall DJ, Marshall VR, Greenberg NM & Tilley WD 2000 Mutations at the boundary of the hinge and ligand binding domain of the androgen receptor confer increased transactivation function. Molecular Endocrinology 15 46-56.
12. Buchanan G, Irvine RA, Coetzee GA & Tilley WD 2001a Contribution of the androgen receptor to prostate cancer predisposition and progression. Cancer Metastasis Reviews 20 207-223.
13. Buchanan G, Greenberg NM, Scher HI, Harris JM, Marshall VR & Tilley WD 2001b Collocation of androgen receptor gene mutations in prostate cancer. Clinical Cancer Research 7 1273-1281.
14. Butler LM, Agus DB, Scher HI, Higgins B, Rose A, Cordon-Cardo C, Thaler HT, Rifkind RA, Marks PA & Richon VM 2000 Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. Cancer Research 60 5165-5170.
15. Caplen NJ, Taylor JP, Statham VS, Tanaka F, Fire A & Morgan RA 2002 Rescue of polyglutamine-mediated cytotoxicity by double-stranded RNA-mediated RNA interference. Human Molecular Genetics 11 175-184.
16. Carducci MA, Gilbert J, Bowling MK, Noe D, Eisenberger MA, Sinibaldi V, Zabelina Y, Chen TL, Grochow LB & Donehower RC 2001 A phase I clinical and pharmacological evaluation of sodium phenylbutyrate on an 120-h infusion schedule. Clinical Cancer Research 7 3047-3055.
17. Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, Vessella R, Rosenfeld MG & Sawyers CL 2004a Molecular determinants of resistance to antiandrogen therapy. Nature Medicine 10 33-39.
18. Cheng S, Brzostek S, Lee SR, Hollenberg AN & Balk SP 2002 Inhibition of the dihydrotestosterone-activated androgen receptor by nuclear receptor corepressor. Molecular Endocrinology 16 1492-1501.
19. Chugh A, Ray A & Gupta JB 2003 Squalene epoxidase as hypocholesterolemic drug target revisited. Progress in Lipid Research 42 37-50.
20. Craft N, Shostak Y, Carey M & Sawyers CL 1999 A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nature Medicine 5 280-285.
21. Culig Z, Hobisch A, Cronauer MV, Radmayr C, Trapman J, Hittmair A, Bartsch G & Klocker H 1994 Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Research 54 5474-5478.
22. Culig Z, Hobisch A, Hittmair A, Peterziel H, Cato AC, Bartsch G & Klocker H 1998 Expression, structure, and function of androgen receptor in advanced prostatic carcinoma. Prostate 35 63-70.
23. Dawson NA & McLeod DG 1995 Dramatic prostate specific antigen decrease in response to discontinuation of megestrol acetate in advanced prostate cancer: expansion of the antiandrogen withdrawal syndrome. Journal of Urology 153 1946-1947.
24. Debes JD, Sebo TJ, Lohse CM, Murphy LM, Haugen DA & Tindall DJ 2003 p300 in prostate cancer proliferation and progression. Cancer Research 63 7638-7640.
25. Dotzlaw H, Moehren U, Mink S, Cato AC, Iniguez Lluhi JA & Baniahmad A 2002 The amino terminus of the human AR is target for corepressor action and antihormone agonism. Molecular Endocrinology 16 661-673.
26. Eder IE, Culig Z, Ramoner R, Thurnher M, Putz T, Nessler-Menardi C, Tiefenthaler M, Bartsch G & Klocker H 2000 Inhibition of LncaP prostate cancer cells by means of androgen receptor antisense oligonucleotides. Cancer Gene Therapy 1 997-1007.
27. Eder IE, Hoffmann J, Rogatsch H, Schafer G, Zopf D, Bartsch G & Klocker H 2002 Inhibition of LNCaP prostate tumor growth in vivo by an antisense oligonucleotide directed against the human androgen receptor. Cancer Gene Therapy 9 117-125.
28. English JM & Cobb MH 2002 Pharmacological inhibitors of MAPK pathways. Trends in Pharmacological Sciences 23 40-45.
29. Fenton MA, Shuster TD, Fertig AM, Taplin ME, Kolvenbag G, Bubley GJ & Balk SP 1997 Functional characterization of mutant androgen receptors from androgen-independent prostate cancer. Clinical Cancer Research 3 1383-1388.
30. Fowler JE Jr & Whitmore WF Jr 1981 The response of metastatic adenocarcinoma of the prostate to exogenous testosterone. Journal of Urology 126 372-375.
31. Geller J, Albert JD, Nachtsheim DA & Loza D 1984a Comparison of prostatic cancer tissue dihydrotestosterone levels at the time of relapse following orchiectomy or estrogen therapy. Journal of Urology 132 693-696.
32. Geller J, de la Vega DJ, Albert JD & Nachtsheim DA 1984b Tissue dihydrotestosterone levels and clinical response to hormonal therapy in patients with advanced prostate cancer. Journal of Clinical Endocrinology and Metabolism 58 36-40.
33. Gelmann EP 2002 Molecular biology of the androgen receptor. Journal of Clinical Oncology 20 3001-3015.
34. Gingrich JR & Greenberg NM 1996 A transgenic mouse prostate cancer model. Toxicologic Pathology 24 502-504.
35. Gingrich JR, Barrios RJ, Morton RA, Boyce BF, DeMayo FJ, Finegold MJ, Angelopoulou R, Rosen JM & Greenberg NM 1996 Metastatic prostate cancer in a transgenic mouse. Cancer Research 56 4096-4102.
36. Gingrich JR, Barrios RJ, Kattan MW, Nahm HS, Finegold MJ & Greenberg NM 1997 Androgen-independent prostate cancer progression in the TRAMP model. Cancer Research 57 4687-4691.
37. Gore SD & Carducci MA 2000 Modifying histones to tame cancer: clinical development of sodium phenylbutyrate and other histone deacetylase inhibitors. Expert Opinion on Investigational Drugs 9 2923-2934.
38. Gottlieb B, Beitel LK, Lumbroso R, Pinsky L & Trifiro M 1999 Update of the androgen receptor gene mutations database. Human Mutation 14 103-114.
39. Greenberg NM, DeMayo F, Finegold MJ, Medina D, Tilley WD, Aspinall JO, Cunha GR, Donjacour AA, Matusik RJ & Rosen JM 1995 Prostate cancer in a transgenic mouse. PNAS 92 3439-3443.
40. Gregory CW, Hamil KG, Kim D, Hall SH, Pretlow TG, Mohler JL & French FS 1998 Androgen receptor expression in androgen-independent prostate cancer is associated with increased expression of androgen-regulated genes. Cancer Research 58 5718-5724.
41. Gregory CW, Johnson RT, Mohler JL, French FS & Wilson EM 2001a Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen. Cancer Research 61 2892-2898.
42. Gregory CW, He B, Johnson RT, Ford OH, Mohler JL, French FS & Wilson EM 2001e A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy. Cancer Research 61 4315-4319.
43. Gregory CW, Fei X, Ponguta LA, He B, Bill HM, French FS & Wilson EM 2004 Epidermal growth factor increases coactivation of the androgen receptor in recurrent prostate cancer. Journal of Biological Chemistry 279 7119-7130.
44. Grenert JP, Sullivan WP, Fadden P, Haystead TA, Clark J, Mimnaugh E, Krutzsch H, Ochel HJ, Schulte TW, Sausville E, Neckers LM & Toft DO 1997 The amino-terminal domain of heat shock protein 90 (hsp90) that binds geldanamycin is an ATP/ADP switch domain that regulates hsp90 conformation. Journal of Biological Chemistry 272 23843-23850.
45. Grossmann ME, Huang H & Tindall DJ 2001 Androgen receptor signaling in androgen-refractory prostate cancer. Journal of the National Cancer Institute 93 1687-1697.
46. Haapala K, Hyytinen ER, Roiha M, Laurila M, Rantala I, Helin HJ & Koivisto PA 2001 Androgen receptor alterations in prostate cancer relapsed during a combined androgen blockade by orchiectomy and bicalutamide. Laboratory Investigation 81 1647-1651.
47. Han G, Foster BA, Mistry S, Buchanan G, Harris JM, Tilley WD & Greenberg NM 2001 Hormone status selects for spontaneous somatic androgen receptor variants that demonstrate specific ligand and cofactor dependent activities in autochthonous prostate cancer. Journal of Biological Chemistry 276 11204-11213.
48. Hobisch A, Culig Z, Radmayr C, Bartsch G, Klocker H & Hittmair A 1995 Distant metastases from prostatic carcinoma express androgen receptor protein. Cancer Research 55 3068-3072.
49. Holzbeierlein J, Lal P, LaTulippe E, Smith A, Satagopan J, Zhang L, Ryan C, Smith S, Scher H, Scardino P, Reuter V & Gerald WL 2004 Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance. American Journal of Pathology 164 217-227.
50. Hryb DJ, Nakhla AM, Kahn SM, St George J, Levy NC, Romas NA & Rosner W 2002 Sex hormone-binding globulin in the human prostate is locally synthesized and may act as an autocrine/paracrine effector. Journal of Biological Chemistry 277 26618-26622.
51. Huan SD, Gerridzen RG, Yau JC & Stewart DJ 1997 Antiandrogen withdrawal syndrome with nilutamide. Urology 49 632-634.
52. Huggins C & Hodges CV 1941 Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Research 1 293-297.
53. Huggins C, Stevens RE & Hodges CV 1941 Studies on prostatic cancer. II. The effect of castration on advanced carcinoma of the prostate gland. Archives of Surgery 43 209-228.
54. Hyytinen ER, Haapala K, Thompson J, Lappalainen I, Roiha M, Rantala I, Helin HJ, Janne OA, Vihinen M, Palvimo JJ & Koivisto PA 2002 Pattern of somatic androgen receptor gene mutations in patients with hormone-refractory prostate cancer. Laboratory Investigation 82 1591-1598.
55. Jarrard DF, Kinoshita H, Shi Y, Sandefur C, Hoff D, Meisner LF, Chang C, Herman JG, Isaacs WB & Nassif N 1998 Methylation of the androgen receptor promoter CpG island is associated with loss of androgen receptor expression in prostate cancer cells. Cancer Research 58 5310-5314.
56. Joyce R, Fenton MA, Rode P, Constantine M, Gaynes L, Kolvenbag G, DeWolf W, Balk S, Taplin ME & Bubley GJ 1998 High dose bicalutamide for androgen independent prostate cancer: effect of prior hormonal therapy. Journal of Urology 159 149-153.
57. Kassouf W, Tanguay S & Aprikian AG 2003 Nilutamide as second line hormone therapy for prostate cancer after androgen ablation fails. Journal of Urology 169 1742-1744.
58. Kelly WK 1998 Endocrine withdrawal syndrome and its relevance to the management of hormone refractory prostate cancer. European Urology 34 18-23.
59. Kelly WK & Scher HI 1993 Prostate specific antigen decline after antiandrogen withdrawal: the flutamide withdrawal syndrome. Journal of Urology 149 607-609.
60. Kelly WK, Slovin S & Scher HI 1997 Steroid hormone withdrawal syndromes. Pathophysiology and clinical significance. Urologic Clinics of North America 24 421-431.
61. Kelly WK, Richon VM, O'Connor O, Curley T, MacGregor-Curtelli B, Tong W, Klang M, Schwarte L, Richardson S, Rosa E, Drobnjak M, Cordon-Cordo C, Chiao JH, Rifkind R, Marks PA & Scher H 2003 Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously. Clinical Cancer Research 9 3578-3588.
62. Kim D, Gregory CW, French FS, Smith GJ & Mohler JL 2002 Androgen receptor expression and cellular proliferation during transition from androgen-dependent to recurrent growth after castration in the CWR22 prostate cancer xenograft. American Journal of Pathology 160 219-226.
63. Koivisto PA & Helin HJ 1999 Androgen receptor gene amplification increases tissue PSA protein expression in hormone-refractory prostate carcinoma. Journal of Pathology 189 219-223.
64. Koivisto P, Visakorpi T & Kallioniemi OP 1996 Androgen receptor gene amplification: a novel molecular mechanism for endocrine therapy resistance in human prostate cancer. Scandinavian Journal of Clinical and Laboratory Investigation Supplementum 226 57-63.
65. Koivisto P, Kononen J, Palmberg C, Tammela T, Hyytinen E, Isola J, Trapman J, Cleutjens K, Noordzij A, Visakorpi T & Kallioniemi OP 1997 Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer. Cancer Research 57 314-319.
66. Kojima S, Suzuki H, Akakura K, Shimbo M, Ichikawa T & Ito H 2004 Alternative antiandrogens to treat prostate cancer relapse after initial hormone therapy. Journal of Urology 171 679-683.
67. Kuratsukuri K, Sugimura K, Harimoto K, Kawashima H & Kishimoto T 1999 'Decoy' of androgen-responsive element induces apoptosis in LNCaP cells. Prostate 41 121-126.
68. Labrie F, Dupont A, Belanger A, Lefebvre FA, Cusan L, Monfette G, Laberge JG, Emond JP, Raynaud JP, Husson JM & Fazekas AT 1983 New hormonal treatment in cancer of the prostate: combined administration of an LHRH agonist and an antiandrogen. Journal of Steroid Biochemistry 19 999-1007.
69. LaTulippe E, Satagopan J, Smith A, Scher H, Scardino P, Reuter V & Gerald WL 2002 Comprehensive gene expression analysis of prostate cancer reveals distinct transcriptional programs associated with metastatic disease. Cancer Research 62 4499-4506.
70. Lee SO, Lou W, Hou M, De Miguel F, Gerber L & Gao AC 2003 Interleukin-6 promotes androgen-independent growth in LNCaP human prostate cancer cells. Clinical Cancer Research 9 370-376.
71. Li P, Lee H, Guo S, Unterman TG, Jenster G & Bai W 2003 AKT-independent protection of prostate cancer cells from apoptosis mediated through complex formation between the androgen receptor and FKHR. Molecular and Cellular Biology 23 104-118.
72. Liao G, Chen LY, Zhang A, Godavarthy A, Xia F, Ghosh JC, Li H & Chen JD 2002 Regulation of androgen receptor activity by the nuclear receptor corepressor SMRT. Journal of Biological Chemistry 278 5052-5061.
73. Linja MJ, Savinainen KJ, Saramaki OR, Tammela TL, Vessella RL & Visakorpi T 2001 Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer. Cancer Research 61 3550-3555.
74. Luo C & Laaja P 2004 Inhibitors of JAKs/STATs and the kinases: a possible new cluster of drugs. Drug Discovery Today 9 268-275.
75. Manni A, Bartholomew M, Caplan R, Boucher A, Santen R, Lipton A, Harvey H, Simmonds M, White-Hershey D & Gordon R 1988 Androgen priming and chemotherapy in advanced prostate cancer: evaluation of determinants of clinical outcome. Journal of Clinical Oncology 6 1456-1466.
76. Marks P, Rifkind RA, Richon VM, Breslow R, Miller T & Kelly WK 2001 Histone deacetylases and cancer: causes and therapies. Nature Reviews Cancer 1 194-202.
77. Mills GB, Kohn E, Lu Y, Eder A, Fang X, Wang H, Bast RC, Gray J, Jaffe R & Hortobagyi G 2003 Linking molecular diagnostics to molecular therapeutics: targeting the PI3K pathway in breast cancer. Seminars in Oncology 30 93-104.
78. Mohler JL, Gregory CW, Ford OH III, Kim D, Weaver CM, Petrusz P, Wilson EM & French FS 2004 The androgen axis in recurrent prostate cancer. Clinical Cancer Research 10 440-448.
79. Nagabhushan M, Miller CM, Pretlow TP, Giaconia JM, Edgehouse NL, Schwartz S, Kung HJ, Vere White RW, Gumerlock PH, Resnick MI, Amini SB & Pretlow TG 1996 CWR22: the first human prostate cancer xenograft with strongly androgen-dependent and relapsed strains both in vivo and in soft agar. Cancer Research 56 3042-3046.
80. Nazareth LV & Weigel NL 1996 Activation of the human androgen receptor through a protein kinase A signaling pathway. Journal of Biological Chemistry 271 19900-19907.
81. Nelson PS, Clegg N, Arnold H, Ferguson C, Bonham M, White J, Hood L & Lin B 2002 The program of androgen-responsive genes in neoplastic prostate epithelium. PNAS 99 11890-11895.
82. Nieh PT 1995 Withdrawal phenomenon with the antiandrogen casodex. Journal of Urology 153 1070-1072.
83. Palvimo JJ, Kallio PJ, Ikonen T, Mehto M & Janne OA 1993 Dominant negative regulation of trans-activation by the rat androgen receptor: roles of the N-terminal domain and heterodimer formation. Molecular Endocrinology 7 1399-1407.
84. Pertschuk LP, Macchia RJ, Feldman JG, Brady KA, Levine M, Kim DS, Eisenberg KB, Rainford E, Prins GS & Greene GL 1994 Immunocytochemical assay for androgen receptors in prostate cancer: a prospective study of 63 cases with long-term follow-up. Annals of Surgical Oncology 1 495-503.
85. Pretlow TG, Wolman SR, Micale MA, Pelley RJ, Kursh ED, Resnick MI, Bodner DR, Jacobberger JW, Delmoro CM & Giaconia JM 1993 Xenografts of primary human prostatic carcinoma. Journal of the National Cancer Institute 85 394-398.
86. Prins GS, Sklarew RJ & Pertschuk LP 1998 Image analysis of androgen receptor immunostaining in prostate cancer accurately predicts response to hormonal therapy. Journal of Urology 159 641-649.
87. Prodromou C, Roe SM, O'Brien R, Ladbury JE, Piper PW & Pearl LH 1997 Identification and structural characterization of the ATP/ADP-binding site in the Hsp90 molecular chaperone. Cell 90 65-75.
88. Rowan BG, Weigel NL & O'Malley BW 2000 Phosphorylation of steroid receptor coactivator-1. Identification of the phosphorylation sites and phosphorylation through the mitogen-activated protein kinase pathway. Journal of Biological Chemistry 275 4475-4483.
89. Sadi MV & Barrack ER 1993 Image analysis of androgen receptor immunostaining in metastatic prostate cancer. Heterogeneity as a predictor of response to hormonal therapy. Cancer 71 2574-2580.
90. Scher HI 2003 Prostate carcinoma: defining therapeutic objectives and improving overall outcomes. Cancer 97 758-771.
91. Scher HI & Kelly WK 1993 Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer. Journal of Clinical Oncology 11 1566-1572.
92. Scher HI & Kolvenbag GJ 1997 The antiandrogen withdrawal syndrome in relapsed prostate cancer. European Urology 31 3-7.
93. Scher HI, Steineck G & Kelly WK 1995 Hormone-refractory (D3) prostate cancer: refining the concept. Urology 46 142-148.
94. Small EJ 1997 Re: Characterization of patients with androgen independent prostatic carcinoma whose serum prostate specific antigen decreased following flutamide withdrawal [letter; comment]. Journal of Urology 158 552.
95. Small EJ & Carroll PR 1994 Prostate-specific antigen decline after casodex withdrawal: evidence for an antiandrogen withdrawal syndrome. Urology 43 408-410.
96. Small EJ & Srinivas S 1995 The antiandrogen withdrawal syndrome. Experience in a large cohort of unselected patients with advanced prostate cancer. Cancer 76 1428-1434.
97. Solit DB, Zheng FF, Drobnjak M, Munster PN, Higgins B, Verbel D, Heller G, Tong W, Cordon-Cardo C, Agus DB, Scher HI & Rosen N 2002 17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts. Clinical Cancer Research 8 986-993.
98. Solit DB, Scher HI & Rosen N 2003 Hsp90 as a therapeutic target in prostate cancer. Seminars in Oncology 30 709-716.
99. Stebbins CE, Russo AA, Schneider C, Rosen N, Hartl FU & Pavletich NP 1997 Crystal structure of an Hsp90-geldanamycin complex: targeting of a protein chaperone by an antitumor agent. Cell 89 239-250.
100. Takahashi S, Inaguma S, Sakakibara M, Cho YM, Suzuki S, Ikeda Y, Cui L & Shirai T 2002 DNA methylation in the androgen receptor gene promoter region in rat prostate cancers. Prostate 52 82-88.
101. Takeda H, Akakura K, Masai M, Akimoto S, Yatani R & Shimazaki J 1996 Androgen receptor content of prostate carcinoma cells estimated by immunohistochemistry is related to prognosis of patients with stage D2 prostate carcinoma. Cancer 77 934-940.
102. Tan J, Sharief Y, Hamil KG, Gregory CW, Zang DY, Sar M, Gumerlock PH, deVere WR, Pretlow TG, Harris SE, Wilson EM, Mohler JL & French FS 1997 Dehydroepiandrosterone activates mutant androgen receptors expressed in the androgen-dependent human prostate cancer xenograft CWR22 and LNCaP cells. Molecular Endocrinology 11 450-459.
103. Taplin ME, Bubley GJ, Ko YJ, Small EJ, Upton M, Rajeshkumar B & Balk SP 1999 Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist. Cancer Research 59 2511-2515.
104. Taplin ME, Halabi S, Rajeshkuman B, McQuain L, Wooda BA, Picus J, Hayes DF, Volgelzang NJ & Small EJ 2001 Androgen receptor mutations in androgen independent prostate cancer (AIPCA) do not correlate with anti-androgen withdrawal response. Proceedings of the American Society of Clinical Oncology 37th Annual Meeting, San Francisco, CA, USA. Abstract 4862.
105. Taplin ME, Rajeshkumar B, Halabi S, Werner CP, Woda BA, Picus J, Stadler W, Hayes DF, Kantoff PW, Vogelzang NJ & Small EJ 2003 Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663. Journal of Clinical Oncology 21 2673-2678.
106. Tilley WD, Marcelli M, Wilson JD & McPhaul 1989 Characterisation and expression of a cDNA encoding the human androgen receptor. PNAS 86 327-331.
107. Tilley WD, Lim-Tio SS, Horsfall DJ, Aspinall JO, Marshall VR & Skinner JM 1994 Detection of discrete androgen receptor epitopes in prostate cancer by immunostaining: measurement by color video image analysis. Cancer Research 54 096-4102.
108. Tilley WD, Buchanan G, Hickey TE & Bentel JM 1996 Mutations in the androgen receptor gene are associated with progression of human prostate cancer to androgen independence. Clinical Cancer Research 2 277-285.
109. Tilley WD, Buchanan G & Coetzee GA 2003 Androgen receptor signaling in prostate cancer. In Hormones Genes and Cancer, pp 288-315. Eds BE Henderson, BA Ponder & RK Ross. New York: Oxford University Press.
110. Ueda T, Bruchovsky N & Sadar MD 2002a Activation of the androgen receptor N-terminal domain by interleukin-6 via MAPK and STAT3 signal transduction pathways. Journal of Biological Chemistry 277 7076-7085.
111. Ueda T, Mawji NR, Bruchovsky N & Sadar MD 2002b Ligand-independent activation of the androgen receptor by interleukin-6 and the role of steroid receptor coactivator-1 in prostate cancer cells. Journal of Biological Chemistry 277 38087-38094.
112. Wainstein MA, He F, Robinson D, Kung HJ, Schwartz S, Giaconia JM, Edgehouse NL, Pretlow TP, Bodner DR & Kursh ED 1994 CWR22: androgen-dependent xenograft model derived from a primary human prostatic carcinoma. Cancer Research 54 6049-6052.
113. Wen Y, Hu MC, Makino K, Spohn B, Bartholomeusz G, Yan DH & Hung MC 2000 HER-2/neu promotes androgen-independent survival and growth of prostate cancer cells through the Akt pathway. Cancer Research 60 6841-6845.
114. Wirth MP & Froschermaier SE 1997 The antiandrogen withdrawal syndrome. Urological Research 25 S67-S71.
115. Yeh S, Miyamoto H, Shima H & Chang C 1998 From estrogen to androgen receptor: a new pathway for sex hormones in prostate. PNAS 95 5527-5532.
116. Yeh S, Kang HY, Miyamoto H, Nishimura K, Chang HC, Ting HJ, Rahman M, Lin HK, Fujimoto N, Hu YC, Mizokami A, Huang KE & Chang C 1999a Differential induction of androgen receptor transactivation by different androgen receptor coactivators in human prostate cancer DU145 cells. Endocrine 11 195-202.
117. Yeh S, Lin HK, Kang HY, Thin TH, Lin MF & Chang C 1999b From HER2/Neu signal cascade to androgen receptor and its coactivators: a novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells. PNAS 96 5458-5463.
118. Zegarra-Moro OL, Schmidt LJ, Huang H & Tindall DJ 2002 Disruption of androgen receptor function inhibits proliferation of androgen-refractory prostate cancer cells. Cancer Research 62 1008-1013.